AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18200773
Drug: Increasing ARB
RxNorm normalized name: revakinagene taroretcel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing ARB dosage
Trial: 11190754
Drug: Budesonide 280
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide 280 micrograms once daily
Trial: 11190754
Drug: Budesonide 140
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide 140 micrograms once daily
Trial: 9355432
Drug: Lidocaine 2.5%
RxNorm normalized name: LIDOCAINE 2.5% OINT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2.5% ointment
Trial: 3534900
Drug: Clonidine (single-dose)
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine (single-dose)
Trial: 29856286
Drug: Conventional psychiatric
RxNorm normalized name: INVESTIGATIONAL DRUGS FOR PSYCHIATRIC DISEASE,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional psychiatric treatment (control group)
Trial: 27327616
Drug: Two injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two injections of MVA (MM group)
Trial: 27327616
Drug: One injection
RxNorm normalized name: naloxone Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One injection of Placebo and one injection of MVA (PM group)
Trial: 12714433
Drug: Isoflavones (biochanin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavones (biochanin or formononetin, 80 mg/d)
Trial: 1713709
Drug: MK-329 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-329 (10 mg orally)
Trial: 6351619
Drug: Oral tinidazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tinidazole, 500 mg twice daily for 5 days
Trial: 6351619
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo with vaginal cream (with or without sulfonamides)
Trial: 6351619
Drug: Vaginal sulfonamide
RxNorm normalized name: 2-acetylamino-1,3,4-thiadiazole-5-sulfonamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal sulfonamide cream with oral placebo
Trial: 29025878
Drug: GLP-1 receptor
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 receptor antagonist exendin 9-39 (Ex9-39)
Trial: 22622049
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of MCV4
Trial: 22622049
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of MCV4
Trial: 22622049
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of MCV4 in subjects with CD4% <15
Trial: 19417618
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg oral rifampin once daily for 7 days
Trial: 15382436
Drug: Endovesical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovesical treatment with Bacillus Calmette Guerin (BCG) for 12 months
Trial: 15382436
Drug: Endovesical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovesical treatment with Bacillus Calmette Guerin (BCG) for 6 months
Trial: 15382436
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no BCG treatment)
Trial: 3293891
Drug: Non-meat protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-meat protein supplement
Trial: 3293891
Drug: Meat protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meat protein supplement
Trial: 31128285
Drug: Antibiotic exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic exposure
Trial: 30392115
Drug: Palbociclib (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palbociclib (125 mg/day; 3 weeks on/1 week off) plus fulvestrant (500 mg)
Trial: 8626983
Drug: House dust
RxNorm normalized name: House dust
DrugBank: House dust (DB10345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: House dust mite inhalation
Trial: 19463380
Drug: Aspirin resistant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin resistant patients (ARU >= 550)
Trial: 19463380
Drug: Aspirin sensitive
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin sensitive patients
Trial: 16556246
Drug: Preventive treatment
RxNorm normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive treatment for headaches
Trial: 30241150
Drug: Gemcitabine 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1,000 mg/m2
Trial: 30241150
Drug: Bleomycin 15
RxNorm normalized name: bleomycin 15 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleomycin 15 IU/m2 and Vincristine 1.4 mg/m2
Trial: 26818604
Drug: Hummus alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hummus alone (2.7 g, 10.8 g, 25 g avCHO)
Trial: 26818604
Drug: Hummus plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hummus plus white bread (2.7 g, 5.4 g, 10.8 g avCHO)
Trial: 26818604
Drug: White bread
RxNorm normalized name: White bread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White bread (25 g avCHO)
Trial: 26818604
Drug: White bread
RxNorm normalized name: White bread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White bread (50 g avCHO)
Trial: 24745810
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (maintaining hemoglobin 10.0 g/dL > hemoglobin ≧ 8.0 g/dL)
Trial: 24745810
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (maintaining hemoglobin ≧ 10.0 g/dL)
Trial: 16842396
Drug: Solifenacin and
RxNorm normalized name: tamsulosin and solifenacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin and warfarin or digoxin
Trial: 12491520
Drug: Peptides/IFA with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptides/IFA with GM-CSF (250 microm subcutaneously daily for 5 days)
Trial: 10850937
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (rhGH) at doses of 0.075 IU/kg, 0.150 IU/kg, and 0.300 IU/kg for 5 postoperative days
Trial: 1818790
Drug: Captopril (41
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (41 +/- 3 mg in three divided doses)
Trial: 1818790
Drug: Enalapril (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (8 +/- 1 mg once daily)
Trial: 31472076
Drug: Drought treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drought treatment
Trial: 11196519
Drug: Home based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home based physical therapy (PT) intervention (education, exercise, and pain relief modalities) delivered by physiotherapists with advanced rheumatology training for 6 weeks.
Trial: 7989934
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy regimens and CNS prophylaxis regimens (intrathecal methotrexate alone or intrathecal methotrexate plus 18 Gy cranial irradiation)
Trial: 29193019
Drug: Lenalidomide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide (25 mg/day orally on days 1-21; 28-day cycles)
Trial: 29193019
Drug: Investigator's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator's choice (IC) therapy (rituximab, gemcitabine, fludarabine, chlorambucil or cytarabine)
Trial: 24740312
Drug: Sugammadex 1
RxNorm normalized name: sugammadex 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 1 mg·kg(‐1)
Trial: 19707086
Drug: Automated telephone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated telephone intervention (daily messages regarding diabetes)
Trial: 15300580
Drug: Nadolol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol (mean dose 62 +/- 25 mg/day, adjusted to decrease resting heart rate by 25%)
Trial: 11123382
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MDMA and ethanol
Trial: 8095150
Drug: epanolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epanolol (200 mg once daily)
Trial: 8095150
Drug: diltiazem (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diltiazem (60 mg three times daily)
Trial: 3688375
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BPD) at concentrations of 0.1 mg/ml, 0.05 mg/ml, 0.005 mg/ml, and 0.0005 mg/ml
Trial: 3688375
Drug: Flunisolide at
RxNorm normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flunisolide at concentrations of 0.25 mg/ml, 0.05 mg/ml, 0.025 mg/ml, and 0.00025 mg/ml
Trial: 3688375
Drug: Propylene glycol
RxNorm normalized name: Propylene Glycol
DrugBank: Propylene glycol (DB01839)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propylene glycol at concentrations of 20 mg/ml and 200 mg/ml
Trial: 23887076
Drug: multimodal analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multimodal analgesic regimen (celecoxib, pregabalin, extended release oxycodone)
Trial: 23887076
Drug: intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous morphine
Trial: 20033052
Drug: Intermediate- or
RxNorm normalized name: Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate- or high-dose methotrexate therapy
Trial: 20033052
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg/m(2)
Trial: 16736065
Drug: Standard formula
RxNorm normalized name: Standard formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard formula and simethicone (6 mg/kg twice a day)
Trial: 12745852
Drug: Ketoconazole cream
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconazole cream
Trial: 10965161
Drug: tolcapone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolcapone (200 mg t.i.d.)
Trial: 8988072
Drug: Atorvastatin 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 0.5 to 80 mg/day
Trial: 7698138
Drug: Diuretic (hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic (hydrochlorothiazide + triamterene)
Trial: 29482588
Drug: Rifaximin 550
RxNorm normalized name: rifAXIMin 550 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin 550 mg twice daily for 18 months
Trial: 29354993
Drug: Conventional western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional western medication (oral acyclovir, vitamin B1, mecobalamin tablets, and interferon injection)
Trial: 24406537
Drug: Cardiac pacing
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac pacing therapy
Trial: 24406537
Drug: No cardiac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No cardiac pacing therapy (Control)
Trial: 9507787
Drug: Enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 5 mg plus diltiazem ER 120 mg or 180 mg
Trial: 3275523
Drug: Sublingual buprenorphine
RxNorm normalized name: buprenorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual buprenorphine (2 mg for 3 weeks, followed by dose reductions and placebo)
Trial: 3275523
Drug: Oral methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methadone (30 mg for 3 weeks, followed by dose reductions and placebo)
Trial: 30422257
Drug: Antipsychotic medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic medications (5 atypical and 2 typical) for 6 weeks
Trial: 14557155
Drug: Epinephrine vs
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine vs Albuterol sulfate (salbutamol)
Trial: 6363660
Drug: Amoxicillin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (40 mg/kg/day in three doses for 10 days)
Trial: 6363660
Drug: Cefaclor (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor (40 mg/kg/day in three doses for 10 days)
Trial: 6363660
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Amoxicillin and Cefaclor)
Trial: 31449469
Drug: Proton beam
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton beam radiation therapy
Trial: 22391537
Drug: CMX001 (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMX001 (0.25 to 2.0 mg/kg single doses; 0.1 to 1.0 mg/kg multiple doses, 3 doses every 6 days)
Trial: 20528000
Drug: Fixed maintenance-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed maintenance-dose budesonide/formoterol
Trial: 20528000
Drug: Adjustable maintenance-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjustable maintenance-dose budesonide/formoterol
Trial: 20528000
Drug: Fixed maintenance-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed maintenance-dose salmeterol/fluticasone propionate
Trial: 17585004
Drug: 5-day antibiotic
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day antibiotic therapy duration
Trial: 17585004
Drug: 10-day antibiotic
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day antibiotic therapy duration
Trial: 17585004
Drug: Dosing frequency
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosing frequency (once daily vs. twice daily)
Trial: 12140400
Drug: Platelet aggregation
RxNorm normalized name: Platelet aggregation inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet aggregation inhibitors
Trial: 12140400
Drug: Cholesterol‐lowering medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholesterol‐lowering medication
Trial: 12140400
Drug: Antidiabetic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidiabetic agents
Trial: 10400003
Drug: Quinapril (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (40 mg daily for two weeks)
Trial: 10400003
Drug: Losartan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50 mg daily for two weeks)
Trial: 7675968
Drug: Scopolamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine (0.5 mg SC)
Trial: 7675968
Drug: Lorazepam (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (2.5 mg PO)
Trial: 2188379
Drug: Bezafibrate 200
RxNorm normalized name: bezafibrate 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate 200 mg three times daily
Trial: 30903423
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of group dynamic assessment and vocabulary exercises
Trial: 21954478
Drug: Saw palmetto
RxNorm normalized name: Saw palmetto
DrugBank: Saw palmetto (DB14360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saw palmetto extract (320 mg/d)
Trial: 19703372
Drug: Intranasal sumatriptan
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal sumatriptan 10 mg
Trial: 9314462
Drug: Monthly intramuscular
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly intramuscular injections of benzathine penicillin G
Trial: 16281190
Drug: Single-session modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-session modified behavioral treatment (SSBT)
Trial: 12061670
Drug: Subcutaneous erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous erythropoietin (600 U/kg per week) and oral iron (3 mg/kg per day)
Trial: 9706280
Drug: Warfarin stroke
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin stroke prophylaxis
Trial: 339132
Drug: Indapamide 2.5
RxNorm normalized name: indapamide 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide 2.5 mg/day for 2 months
Trial: 31078463
Drug: Axitinib 5
RxNorm normalized name: axitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib 5 mg orally twice daily and pembrolizumab 200 mg intravenously for 30 min on day 8 and every 3 weeks for cycles of 6 weeks for up to 2 years, followed by escalating doses of axitinib (2-10 mg) plus flat dose pembrolizumab.
Trial: 15763453
Drug: Terbutaline 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline 6 mg
Trial: 10102971
Drug: Asacol (mesalazine)
RxNorm normalized name: mesalamine Rectal Foam [Asacol]
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Asacol (mesalazine) 1.2 g daily for 12 months in Group A (1-2 years remission)
Trial: 10102971
Drug: Asacol (mesalazine)
RxNorm normalized name: mesalamine Rectal Foam [Asacol]
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Asacol (mesalazine) 1.2 g daily for 12 months in Group B (over 2 years remission)
Trial: 429787
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated influenza vaccine containing the recombinant of A/Victoria/3/75 with A/PR/8/34 virus
Trial: 30308538
Drug: Short (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short (24 hours) antibiotic administration
Trial: 30308538
Drug: Extended (>24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended (>24 hours) antibiotic administration
Trial: 23225308
Drug: Diclofenac suppository-nabumetone
RxNorm normalized name: diclofenac Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac suppository-nabumetone combination therapy
Trial: 23225308
Drug: Nabumetone administration
RxNorm normalized name: Nabumetone
DrugBank: Nabumetone (DB00461)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nabumetone administration
Trial: 21647699
Drug: Oxygen administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen administration (5 l/min) during spontaneous breathing in diabetic participants
Trial: 21647699
Drug: Oxygen administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen administration (5 l/min)
Trial: 8538183
Drug: High-dose 13-cis-retinoic
RxNorm normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose 13-cis-retinoic acid (13cRA)
Trial: 8538183
Drug: High-dose followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose followed by low-dose 13-cis-retinoic acid (13cRA)
Trial: 8538183
Drug: Adjuvant high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant high-dose 13-cis-retinoic acid (13cRA)
Trial: 2142026
Drug: CGS 16949A
RxNorm normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGS 16949A 0.3 mg twice daily
Trial: 2142026
Drug: CGS 16949A
RxNorm normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGS 16949A 1.0 mg twice daily
Trial: 2142026
Drug: CGS 16949A
RxNorm normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGS 16949A 2.0 mg twice daily
Trial: 2142026
Drug: CGS 16949A
RxNorm normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGS 16949A 0.1 mg twice daily
Trial: 2142026
Drug: CGS 16949A
RxNorm normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGS 16949A (all doses)
Trial: 23558857
Drug: Attribution retraining
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attribution retraining group therapy (ARGT)
Trial: 15389174
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy in addition to the stay-active concept
Trial: 9553435
Drug: Extracorporeal ultraviolet
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal ultraviolet blood irradiation (EUVBR) with antibiotic therapy
Trial: 7851112
Drug: Dietary supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplementation with beta-carotene (30 mg daily)
Trial: 26994091
Drug: Ritonavir-boosted lopinavir
RxNorm normalized name: lopinavir / ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir-boosted lopinavir (400/100 mg) with tenofovir disoproxil/emtricitabine (245/200 mg) once daily
Trial: 26994091
Drug: Maraviroc (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maraviroc (300 mg) with tenofovir disoproxil/emtricitabine (245/200 mg) once daily
Trial: 20388648
Drug: Randomized treatments
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized treatments with n-3 polyunsaturated fatty acid or rosuvastatin
Trial: 15754239
Drug: Operative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative therapy (IVO)